Guidant Corp., the heart device company that agreed this week to be acquired by Boston Scientific Corp., on Friday posted weaker quarterly earnings as sales of its profitable implantable defibrillators dropped 19%, sending its shares lower.
*For more on this story,
read the full Reuters article.
